H. Eric Cannon, PharmD, FAMCP: Money can’t solve all our problems, but it sure helps. Can you afford your co-pays? Poverty is definitely playing into this. Homeless people [are affected]. We’re starting to work with populations that have recently been discharged from prison. There are people who don’t feel accepted. That acceptance goes across a lot of levels. If I found a physician or a therapist, but I don’t feel accepted or I don’t feel that it’s an inclusive environment, I might not keep going. That plays a role in how a patient feels. Finding ways to be more inclusive is critical for all of us.
Michael Rothrock, MBA, MHA: This is a continuing theme of our last couple of topics. We’ve [spoken] about the socioeconomic status of individuals who are the most challenging to identify and get access and care to, based on their lower income levels. At the end of the day, it comes down to education, affordability, access to care, promotion, and awareness through the workforce and your own internal HR [human resources] departments to say that there are self-help opportunities and ways to get in touch with providers or caregivers to assist you if you or a family member are experiencing symptoms of depression.
This holistic approach becomes much more magnified, and we’re much more aware as a society. We went through 2-plus years of COVID-19, and we’re trying to find the best way to [reach] these patients on a regular basis, or at least provide them the help or care they need so they can invest in themselves. As Dr Cannon mentioned, affordability is one thing. If they can’t afford the co-pays, that’s going to be a challenge. But other ways of finding care through local communities—self-help books, manufacturer-sponsored programs, church groups, even your own colleagues and friends—is something we need to see as an opportunity to [reach] these patients more frequently.
Transcript edited for clarity.
Social Determinants of Health in MDD
Key social determinants affecting MDD are evaluated by Michael Rothrock, MBA, MHA, and H. Eric Cannon, PharmD, FAMCP.
EP: 1.Unmet Needs in Treatment of MDD
EP: 2.MDD Treatment Landscape
EP: 3.Potential Consequences of Recurrent or Poorly Controlled MDD
EP: 4.Burden of Treatment Failure in MDD
EP: 5.Importance of Early Effective Treatment of MDD
EP: 6.Evaluating MDD Treatment Attributes
EP: 7.Considerations for Newly Launched MDD Treatments
EP: 8.Healthcare Disparities Within Major Depressive Disorder
EP: 9.MDD Treatment Disparities Across Patient Populations
EP: 10.Social Determinants of Health in MDD
EP: 11.Impact of COVID-19 on Demand for Mental Health Services
EP: 12.Health Care Disparities Within Major Depressive Disorder (MDD)
EP: 13.MDD Treatment Disparities Across Patient Populations: Part 2
EP: 14.Social Determinants of Health in MDD: Part 2
EP: 15.Population Health Approach in MDD
EP: 16.Factors Affecting MDD Treatment Adherence
EP: 17.Supporting Adherence for Patients with MDD
EP: 18.Aligning MDD Treatment Goals for Payers and Patients
EP: 19.The Impact of Early Effective Treatment in MDD
EP: 20.Key Contributors to Long-term Outcomes for Patients With MDD
H. Eric Cannon, PharmD, FAMCP: Money can’t solve all our problems, but it sure helps. Can you afford your co-pays? Poverty is definitely playing into this. Homeless people [are affected]. We’re starting to work with populations that have recently been discharged from prison. There are people who don’t feel accepted. That acceptance goes across a lot of levels. If I found a physician or a therapist, but I don’t feel accepted or I don’t feel that it’s an inclusive environment, I might not keep going. That plays a role in how a patient feels. Finding ways to be more inclusive is critical for all of us.
Michael Rothrock, MBA, MHA: This is a continuing theme of our last couple of topics. We’ve [spoken] about the socioeconomic status of individuals who are the most challenging to identify and get access and care to, based on their lower income levels. At the end of the day, it comes down to education, affordability, access to care, promotion, and awareness through the workforce and your own internal HR [human resources] departments to say that there are self-help opportunities and ways to get in touch with providers or caregivers to assist you if you or a family member are experiencing symptoms of depression.
This holistic approach becomes much more magnified, and we’re much more aware as a society. We went through 2-plus years of COVID-19, and we’re trying to find the best way to [reach] these patients on a regular basis, or at least provide them the help or care they need so they can invest in themselves. As Dr Cannon mentioned, affordability is one thing. If they can’t afford the co-pays, that’s going to be a challenge. But other ways of finding care through local communities—self-help books, manufacturer-sponsored programs, church groups, even your own colleagues and friends—is something we need to see as an opportunity to [reach] these patients more frequently.
Transcript edited for clarity.
Prior Authorizations and the Adverse Impact on Continuity of Care
April 2nd 2025Prior authorizations create substantial administrative and financial burdens on physicians and patients and can disrupt the continuity of care.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Updated KRYSTAL-7 Data Show PFS Beyond 27 Months for Adagrasib Plus Pembro in First-Line Treatment of KRAS-Mutated NSCLC
March 28th 2025Phase 2 results reported at the European Lung Cancer Conference show a favorable signal for overall survival for the first-line treatment of KRAS-mutated non–small cell lung cancer (NSCLC). A phase 3 trial is enrolling now.
Read More
Five Years Later: Ongoing COVID-19 Challenges, Next Steps
December 23rd 2024On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.
Listen
Prevalence, Severity of Astigmatism Increased in Children After Pandemic
March 26th 2025Both refractive and corneal astigmatism saw an increase in prevalence in children after the COVID-19 pandemic, with corneal changes potentially playing a part.
Read More
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More
Prior Authorizations and the Adverse Impact on Continuity of Care
April 2nd 2025Prior authorizations create substantial administrative and financial burdens on physicians and patients and can disrupt the continuity of care.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Updated KRYSTAL-7 Data Show PFS Beyond 27 Months for Adagrasib Plus Pembro in First-Line Treatment of KRAS-Mutated NSCLC
March 28th 2025Phase 2 results reported at the European Lung Cancer Conference show a favorable signal for overall survival for the first-line treatment of KRAS-mutated non–small cell lung cancer (NSCLC). A phase 3 trial is enrolling now.
Read More
Five Years Later: Ongoing COVID-19 Challenges, Next Steps
December 23rd 2024On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.
Listen
Prevalence, Severity of Astigmatism Increased in Children After Pandemic
March 26th 2025Both refractive and corneal astigmatism saw an increase in prevalence in children after the COVID-19 pandemic, with corneal changes potentially playing a part.
Read More
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More